IGFL2 and non-small cell lung carcinoma: In our study, we found that IGFL2-AS1 is up-regulated in PD-treated NSCLCs, and the K–M analysis also shows that the low expression of IGFL2-AS1 is related to the poor prognosis of NSCLC, suggesting a protective role of IGFL2-AS1 in NSCLC.